Engineering commensal bacteria for prophylaxis against infection

Current Opinion in Biotechnology

Volumn 23, Issue 6, 2012, Pages 924-930

  Goh, Yih Lin ^a   He, HongFei ^b   March, John C ^a  

^a Department of Biological and Environmental Engineering   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAUSES OF DEATH; HUMAN BODIES; INFECTIOUS DISEASE; LOW COSTS; PATHOGENIC INFECTIONS;

GENETIC ENGINEERING;

BACTERIA;

BACTERIAL ANTIGEN; BACTERIAL TOXIN; BACTERIOCIN; INFLUENZA VACCINE; LACTOBACILLUS VACCINE; PROBIOTIC AGENT;

ANTHRAX; BACILLUS CEREUS; BACTERIAL CELL; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CHOLERA; COMMENSAL; COMMENSAL BACTERIUM; ESCHERICHIA COLI; GENETIC ENGINEERING; HUMAN; INFECTION PREVENTION; INFLUENZA A (H5N1); LACTOBACILLUS; LISTERIA MONOCYTOGENES; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUORUM SENSING; REGULATORY MECHANISM; REVIEW; SALMONELLA ENTERICA; VIBRIO CHOLERAE; VIRUS CELL INTERACTION; VIRUS INFECTION;

ANIMALS; BACTERIA; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; INFECTION CONTROL; VACCINES, SYNTHETIC; VIRULENCE; VIRUSES;

EID: 84869872741     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2012.03.004     Document Type: Review

References (48)

1. Peterson J., Garges S., Giovanni M., McInnes P., Wang L., Schloss J.A., Bonazzi V., McEwen J.E., Wetterstrand K.A., Deal C., et al. The NIH Human Microbiome Project. Genome Res 2009, 19:2317-2323.
2. Blaser M.J. Harnessing the power of the human microbiome. Proc Natl Acad Sci U S A 2010, 107:6125-6126.
3. Proctor L.M. The Human Microbiome Project in 2011 and beyond. Cell Host Microbe 2011, 10:287-291.
4. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., Nielsen T., Pons N., Levenez F., Yamada T., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
5. Kuczynski J., Lauber C.L., Walters W.A., Parfrey L.W., Clemente J.C., Gevers D., Knight R. Experimental and analytical tools for studying the human microbiome. Nat Rev Genet 2012, 13:47-58.
6. Bagnoli F., Baudner B., Mishra R.P.N., Bartolini E., Fiaschi L., Mariotti P., Nardi-Dei V., Boucher P., Rappuoli R. Designing the next generation of vaccines for global public health. OMICS: J Integr Biol 2011, 15:545-566.
7. Hill D.A., Hoffmann C., Abt M.C., Du Y., Kobuley D., Kirn T.J., Bushman F.D., Artis D. Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. Mucosal Immunol 2010, 3:148-158.
8. Tlaskalova-Hogenova H., Stepankova R., Kozakova H., Hudcovic T., Vannucci L., Tuckova L., Rossmann P., Hrncir T., Kverka M., Zakostelska Z., et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011, 8:110-120.
9. Wardwell L.H., Huttenhower C., Garrett W.S. Current concepts of the intestinal microbiota and the pathogenesis of infection. Curr Infect Dis Rep 2011, 13:28-34.
10. Villena J., Oliveira M.L.S., Ferreira P.C.D., Salva S., Alvarez S. Lactic acid bacteria in the prevention of pneumococcal respiratory infection: future opportunities and challenges. Int Immunopharmacol 2011, 11:1633-1645.
11. Wells J.M., Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008, 6:349-362.
12. Wells J. Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Annual Review of Food Science and Technology 2011, vol 2.2:423-445.
13. Cruz Martin M., Pant N., Ladero V., Gunaydin G., Andersen K.K., Alvarez B., Martinez N., Alvarez M.A., Hammarstrom L., Marcotte H. Integrative expression system for delivery of antibody fragments by lactobacilli. Appl Environ Microbiol 2011, 77:2174-2179.
14. Daniel C., Roussel Y., Kleerebezem M., Pot B. Recombinant lactic acid bacteria as mucosal biotherapeutic agents. Trends Biotechnol 2011, 29:499-508.
15. Bermudez-Humaran L.G. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin 2009, 5:264-267.
16. Bermudez-Humaran L.G., Kharrat P., Chatel J.M., Langella P. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 2011, (10 Suppl 1.):S4.
17. Waters C.M., Bassler B.L. Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol 2005, 21:319-346.
18. Duan F.P., March J.C. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc Natl Acad Sci U S A 2010, 107:11260-11264.
19. Fernandes R., Roy V., Wu H.C., Bentley W.E. Engineered biological nanofactories trigger quorum sensing response in targeted bacteria. Nat Nanotechnol 2010, 5:213-217.
20. Saeidi N., Wong C.K., Lo T.M., Nguyen H.X., Ling H., Leong S.S.J., Poh C.L., Chang M.W. Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen. Mol Syst Biol 2011, 7:521-532.
21. Rasko D.A., Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 2010, 9:117-128.
22. Paton A.W., Jennings M.P., Morona R., Wang H., Focareta A., Roddam L.F., Paton J.C. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 2005, 128:1219-1228.
23. Focareta A., Paton J.C., Morona R., Cook J., Paton A.W. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 2006, 130:1688-1695.
24. Koo O.K., Amalaradjou M.A.R., Bhunia A.K. Recombinant probiotic expressing listeria adhesion protein attenuates Listeria monocytogenes virulence in vitro. PLoS One 2012, 7:e29277.
25. Sanchez B., Lopez P., Gonzalez-Rodriguez I., Suarez A., Margolles A., Urdaci M.C. A flagellin-producing Lactococcus strain: interactions with mucin and enteropathogens. FEMS Microbiol Lett 2011, 318:101-107.
26. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
27. Daniel C., Sebbane F., Poiret S., Goudercourt D., Dewulf J., Mullet C., Simonet M., Pot B. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV. Vaccine 2009, 27:1141-1144.
28. Wolfenden R.E., Layton S.L., Wolfenden A.D., Khatiwara A., Gaona-Ramirez G., Pumford N.R., Cole K., Kwon Y.M., Tellez G., Bergman L.R., Hargis B.M. Development and evaluation of candidate recombinant Salmonella-vectored Salmonella vaccines. Poult Sci 2010, 89:2370-2379.
29. Yamamoto S., Wada J., Katayama T., Jikimoto T., Nakamura M., Kinoshita S., Lee K.M., Kawabata M., Shirakawa T. Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model. Vaccine 2010, 28:6684-6691.
30. Hernani Mde L., Ferreira P.C., Ferreira D.M., Miyaji E.N., Ho P.L., Oliveira M.L. Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases Pneumococcal nasopharyngeal colonization in mice. FEMS Immunol Med Microbiol 2011, 62:263-272.
31. Vintini E., Villena J., Alvarez S., Medina M. Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice. Clin Exp Immunol 2010, 159:351-362.
32. Mohamadzadeh M., Duong T., Sandwick S.J., Hoover T., Klaenhammer T.R. Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc Natl Acad Sci U S A 2009, 106:4331-4336.
33. Mohamadzadeh M., Durmaz E., Zadeh M., Pakanati K.C., Gramarossa M., Cohran V., Klaenhammer T.R. Targeted expression of anthrax protective antigen by Lactobacillus gasseri as an anthrax vaccine. Future Microbiol 2010, 5:1289-1296.
34. Fahey J.V., Bodwell J.E., Hickey D.K., Ghosh M., Muia M.N., Wira C.R. New approaches to making the microenvironment of the female reproductive tract hostile to HIV. Am J Reprod Immunol 2011, 65:334-343.
35. Lagenaur L.A., Sanders-Beer B.E., Brichacek B., Pal R., Liu X., Liu Y., Yu R., Venzon D., Lee P.P., Hamer D.H. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 2011, 4:648-657.
36. Yu R.R., Cheng A.T., Lagenaur L.A., Huang W., Weiss D.E., Treece J., Sanders-Beer B.E., Hamer D.H., Lee P.P., Xu Q., Liu Y. A Chinese rhesus macaque (Macaca mulatta) model for vaginal Lactobacillus colonization and live microbicide development. J Med Primatol 2009, 38:125-136.
37. Vangelista L., Secchi M., Liu X., Bachi A., Jia L., Xu Q., Lusso P. Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. Antimicrob Agents Chemother 2010, 54:2994-3001.
38. Duval M., Lewis C.J., Nomellini J.F., Horwitz M.S., Smit J., Cavacini L.A. Enhanced neutralization of HIV by antibodies displayed on the S-layer of Caulobacter crescentus. Antimicrob Agents Chemother 2011, 55:5547-5552.
39. Nomellini J.F., Li C., Lavallee D., Shanina I., Cavacini L.A., Horwitz M.S., Smit J. Development of an HIV-1 specific microbicide using Caulobacter crescentus S-layer mediated display of CD4 and MIP1alpha. PLoS One 2010, 5:e10366.
40. Lei H., Xu Y., Chen J., Wei X., Lam D.M. Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 2010, 407:319-324.
41. Lei H., Sheng Z., Ding Q., Chen J., Wei X., Lam D.M.K., Xu Y. Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B. Clin Vaccine Immunol 2011, 18:1046-1051.
42. Burrill D.R., Boyle P.M., Silver P.A. A new approach to an old problem: synthetic biology tools for human disease and metabolism. Cold Spring Harb Symp Quant Biol 2011.
43. Baker M. Better living through microbes. Nat Biotechnol 2005, 23:645-647.
44. Lee P. Biocontainment strategies for live lactic acid bacteria vaccine vectors. Bioeng Bug 2010, 1:75-77.
45. Curtis M.M., Sperandio V. A complex relationship: the interaction among symbiotic microbes, invading pathogens, and their mammalian host. Mucosal Immunol 2011, 4:133-138.
46. Hughes D.T., Terekhova D.A., Liou L., Hovde C.J., Sahl J.W., Patankar A.V., Gonzalez J.E., Edrington T.S., Rasko D.A., Sperandio V. Chemical sensing in mammalian host-bacterial commensal associations. Proc Natl Acad Sci U S A 2010, 107:12734.
47. Weber W., Fussenegger M. Emerging biomedical applications of synthetic biology. Nat Rev Genet 2012, 13:21-35.
48. Ruder W.C., Lu T., Collins J.J. Synthetic biology moving into the clinic. Science 2011, 333:1248-1252.